Quality by Design in Pharmaceutical Analysis
(Im Auftrag der European Compliance Academy)

Quality by Design in Pharmaceutical Analysis <p>(Im Auftrag der European Compliance Academy)

1-2 October 2015

Budapest, Hungary

Seminar Nr. 9236

Unser Seminarservice

Kosten

Die Veranstaltung hat bereits stattgefunden

Rückfragen unter:
Tel.: 06221 / 84 44 0 E-Mail: info@concept-heidelberg.de

Sprecher

Dr Joachim Ermer, Sanofi, Germany
Patrick Jackson, GSK, United Kingdom

Zielsetzung

The aim of this two day course is to provide guidance on how QbD principles can be applied to analytical methods and identify the opportunities, not only for new development products, but also for drugs already marketed. This course will deal among others with the following questions:

What are the opportunities of applying QbD and life cycle approach to analytical methods?
What is the current status of analytical QbD (USP, FDA-EMA, FDA Draft Guidance Method Validation)?
How can the Analytical Target Profile increase regulatory flexibility?
Why is it important to have a clear understanding and expectation of method performance?
What is the impact of QbD on method development, validation and transfer?
What is the advantage of the 3-Stage lifecycle approach to validation?
How can QbD also benefit marketed products?

A number of interactive workshops will be provided throughout the two days which will enable delegates to to apply what they have learnt and to discuss the concepts in more detail. Delegates will have the opportunity to work through the whole QbD process by gaining “hands-on experience” using a number of case studies.

Hintergrund

The pharmaceutical industry is currently embracing QbD concepts to help improve the robustness of manufacturing processes and to facilitate continuous improvement strategies to enhance product quality and manufacturing productivity. QbD ensures product and process performance characteristics are scientifically designed to meet specific objectives, not merely empirically derived from the performance of test batches. Key QbD concepts are described in ICH guidelines Q8 (R1) Pharmaceutical Development, Q9 Quality Risk management and Q10 Pharmaceutical Quality System. The same opportunities exist for applying QbD to analytical methods as they do for manufacturing processes.

During the course an overview of a position paper written jointly by PhRMA and EFPIA and of a new USP Stimuli Article will be provided which use a new concept called the Analytical Target Profile (ATP). It parallels the concept of a Quality Target Product Profile described and defined in ICH Q8 and defines the performance requirements for the measurement of a given Quality Attribute. The ATP will be used to drive all analytical life cycle activities within the three stages (Method Design, Method Performance Qualification, Continued Method Performance Verification) including change control. It is hoped that greater continuous improvement of methods can also be facilitated if regulatory authorities agree with and approve the ATP statement. Each method conforming to the ATP requirements would be implemented by the company’s internal change control management system, thus providing regulatory flexibility. Risk assessment tools and statistical methods used to facilitate understanding of the method performance characteristics (e.g. accuracy and precision) and their acceptance criteria will also be covered. Traditional method validation will be compared to a QbD approach which includes life-cycle aspects instead of a one off validation exercise.

Note: In order to fully benefit from the workshops, attendees should preferably bring a notebook with Excel®.

Zielgruppe

This course is designed for analytical managers and scientists who are responsible for performing or reviewing activities like method development, validation, transfer, operation and monitoring of methods in a QC environment, statistical evaluation of method performance, analytical change control etc.

In addition, QA and regulatory affairs professionals will benefit from this course by gaining an understanding in future CMC trends. This will aid more effective multifunctional discussions on these topics within industry.

Programm

Introduction to Analytical QbD
Overview on proposals of EFPIA/PhRMA Paper and USP Stimuli Article
Analytical Target Profile
Application of QbD principles to pharmaceutical analysis
Change Control and regulatory flexibility

Design Intent of the Method – ATP and Business Requirements
Linkage with process control strategy (critical quality attributes)
Definition of ATP
Method Performance Characteristics and their criteria
Business requirements of method

Understanding the ATP – Analytical Variability
Sources of analytical variability
Method performance characteristics: accuracy and precision
Method performance and expectation ranges for experimental results and statistical parameters
Decision rules and establishment of acceptance limits

QbD Method Development
Method design
Method selection
Risk assessment
Control Definition of method (robustness and ruggedness testing)

Traditional Validation versus QbD Validation
“Translation” of ATP into specific method requirements
Identification of relevant performance parameters
Establishment of appropriate acceptance criteria
Life-cycle approach, continued performance verification

Life-cycle and change management
Knowledge management system
Analytical Method Transfer
Routine method operation
Continuous method verification, change control and regulatory implications

Wrap up & Final Discussion
The concepts and tools used over the two days will be summarised and future implications and opportunities of applying QbD principles to analytical measurements will be discussed. Delegates will be given time to ask questions on how they can apply what they have learnt to their own analytical methods.

....Plus Five hours of interactive workshops!

Zurück

Quality by Design in Pharmaceutical Analysis(Im Auftrag der European Compliance Academy)